Gene fusions between androgen-regulated genes and ERG (e.g., TMPRSS2-ERG) occur in ~50% of prostate cancers, with the alteration resulting in the presence of ERG overexpression in both early and late-stage prostate cancer (248, 249). The gene discussed is TMPRSS2; the disease is prostate carcinoma.